	US 11,744,813 B2
	Modifier system for compositions containing layered double hydroxide
Elizabeth King, Calne (GB); Marcelo Leonardo Bravo Cordero, Oxford (GB); and Ann Taylor-Hutchinson, Hucknall (GB)
Assigned to Oxford Pharmascience Limited, Camden London (GB)
Filed by OXFORD PHARMASCIENCE LIMITED, Camden London (GB)
Filed on Nov. 4, 2021, as Appl. No. 17/519,068.
Application 17/519,068 is a continuation of application No. 16/343,812, abandoned, previously published as PCT/GB2017/053237, filed on Oct. 27, 2017.
Claims priority of application No. 1618204 (GB), filed on Oct. 27, 2016.
Prior Publication US 2022/0054437 A1, Feb. 24, 2022
Int. Cl. A61K 31/192 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/20 (2006.01); A61K 47/24 (2006.01); A61K 47/52 (2017.01)

CPC A61K 31/192 (2013.01) [A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/20 (2013.01); A61K 47/24 (2013.01); A61K 47/52 (2017.08)]

14 Claims

1. A composition comprising: i) one or more layered double hydroxide (LDH)-active anion materials comprising an LDH matrix intercalated with an active anion, and ii) a modifier system comprising a) a surfactant, in combination with sodium carbonate, wherein the active anion is ibuprofen or naproxen,

wherein when the active anion is ibuprofen, the surfactant is selected from poloxamer, lecithin, and sodium lauryl sulfate, and the composition has a weight ratio 1:1:0.25 to 1:1:1 (LDH matrix:sodium carbonate:surfactant);

wherein when the active anion is naproxen, the surfactant is lecithin or poloxamer, and when the surfactant is lecithin, the composition has a weight ratio of 8:5:5 (LDH matrix:sodium carbonate:surfactant) and when the surfactant is poloxamer, the composition has a weight ratio of 8:5:1.25 to 8:5:5 (LDH matrix:sodium carbonate:surfactant).